173 related articles for article (PubMed ID: 37560283)
21. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program.
Chao TF; Unverdorben M; Kirchhof P; Koretsune Y; Yamashita T; Crozier RA; Pecen L; Chen C; Borrow AP; De Caterina R
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902656
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
[TBL] [Abstract][Full Text] [Related]
23. Lessons derived from post authorisation safety studies (ETNA-AF and XANTUS) on once daily direct oral anticoagulants for atrial fibrillation.
Cemin R; Cappato R
Int J Cardiol; 2024 Mar; 398():131618. PubMed ID: 38030040
[TBL] [Abstract][Full Text] [Related]
24. Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan).
Yamashita T; Koretsune Y; Nagao T; Shiosakai K
J Arrhythm; 2021 Apr; 37(2):370-383. PubMed ID: 33850579
[TBL] [Abstract][Full Text] [Related]
25. Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry.
Barón-Esquivias G; Roldán Rabadán I; García Quintana A; Cerezo Manchado JJ; Antorrena Miranda I; Gómez-Barrado JJ; Pérez Paredes M; Santas E; Pindado Rodríguez J; Muñoz-Robles JA; Oliver-Miñarro D; Santamaría A;
Future Cardiol; 2020 Sep; 16(5):469-480. PubMed ID: 32228182
[No Abstract] [Full Text] [Related]
26. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
[TBL] [Abstract][Full Text] [Related]
27. Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.
Yamashita T; Koretsune Y; Ishikawa M; Shiosakai K; Kogure S
J Arrhythm; 2019 Feb; 35(1):121-129. PubMed ID: 30805052
[TBL] [Abstract][Full Text] [Related]
28. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
[TBL] [Abstract][Full Text] [Related]
29. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients - A Subanalysis of the ENVISAGE-TAVI AF Trial.
Watanabe Y; Hayashida K; Yamamoto M; Yamanaka F; Yamasaki K; Naganuma T; Ohno Y; Yamawaki M; Morioka N; Mizutani K; Tada N; Ueno H; Nishina H; Izumo M; Nakajima Y; Ando K; Takagi K; Kimura T; Sugio K; Dangas G; Van Mieghem NM; Hengstenberg C; Chen C; Jin J; Unverdorben M; Saito S
Circ J; 2022 Oct; 86(11):1756-1763. PubMed ID: 35965066
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
31. Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European Population.
Blann AD; Pisters R; Lip GYH
JACC Clin Electrophysiol; 2016 Feb; 2(1):47-54. PubMed ID: 29766853
[TBL] [Abstract][Full Text] [Related]
32. [One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe].
Ameri P; Riva L; Toma M; Di Pasquale G; De Caterina R
G Ital Cardiol (Rome); 2020 Jul; 21(7):546-557. PubMed ID: 32555574
[TBL] [Abstract][Full Text] [Related]
33. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry.
Kim JY; Choi EK; Lim HE; Oh YS; Cho Y; On YK
J Korean Med Sci; 2022 Dec; 37(48):e335. PubMed ID: 36513051
[TBL] [Abstract][Full Text] [Related]
35. Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M; Al-Saady N; Hjortshøj SP; Goudev A; Huber K; Cohen A; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Clin Res Cardiol; 2020 Aug; 109(8):1018-1024. PubMed ID: 31915996
[TBL] [Abstract][Full Text] [Related]
36. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.
Cohen AT; Ay C; Hainaut P; Décousus H; Hoffmann U; Gaine S; Coppens M; da Silva PM; Castro DJ; Amann-Vesti B; Brüggenjürgen B; Levy P; Bastida JL; Vicaut E; Laeis P; Fronk EM; Zierhut W; Malzer T; Bramlage P; Agnelli G;
Thromb J; 2018; 16():9. PubMed ID: 29719492
[TBL] [Abstract][Full Text] [Related]
37. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
[TBL] [Abstract][Full Text] [Related]
38. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Wang Y; Li L; Wei Z; Lu S; Liu W; Zhang J; Feng J; Wang D
Medicines (Basel); 2023 Jan; 10(1):. PubMed ID: 36662497
[TBL] [Abstract][Full Text] [Related]
40. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
Diemberger I; Fumagalli S; Mazzone AM; Bakhai A; Reimitz PE; Pecen L; Manu MC; Gordillo de Souza JA; Kirchhof P; De Caterina R
Europace; 2022 Oct; 24(9):1404-1411. PubMed ID: 35512229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
